Gland Pharma to invest Rs 400 Cr to expand its Telangana plant

Gland Pharma announced today that it will invest Rs 400 crore to expand its existing facility in Genome Valley here to manufacture biologicals, biosimilars, antibodies, and recombinant insulin. According to a state government press release, the expanded facility will have the potential to employ more than 500 qualified, skilled, and semi-skilled workers, mostly from the surrounding area. The company established their biopharmaceutical facility in Genome Valley in February of last year with an investment of Rs 300 crore to manufacture vaccines, biologicals, biosimilars, antibodies, and other products.

According to the company, the expanded site will be built in accordance with the GMP guidelines applicable to the respective product lines and will meet the national and international regulations to be followed in the manufacturing of biological products as applicable. The announcement came following a meeting between Telangana Industries Minister KT Rama Rao and Gland Pharma's Managing Director and Chief Executive Officer Srinivas Sadu. Srinivas Sadu said, "We are delighted to collaborate with the Government of Telangana on its vision of making the State a hub for global pharmaceutical requirements, by expanding our Bio-CDMO facilities in Shamirpet. This project investment is estimated to be about Rs 400 crore and expected to generate employment to about 500 personnel." Rama Rao said, "I am delighted that Gland Pharma will be investing Rs 400 crores in expanding their footprint in Hyderabad and will create 500 more jobs in Telangana."